Alternatively, advanced cSCC can be treated systemically with cemiplimab (anti-PD-1 ICI), which was FDA-approved for patients with R/M cSCC in September 2018 (Table 2) [98] based on a trial demonstrating a ORR of 47% [99]. Here, PDCD1 is linked to skin squamous cell carcinoma.